Covered recipient · General Payments record
EDUARDO DUSTY LUNA
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$24,743.20
146 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $9,594.79 | 34 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $9,081.25 | 8 |
| Food and Beverage | $3,010.42 | 97 |
| Consulting Fee | $3,000.00 | 5 |
| Education | $56.74 | 2 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Abbott Laboratories | $23,899.60 | 96 |
| Amgen Inc. | $148.35 | 9 |
| Merck Sharp & Dohme Corporation | $117.22 | 12 |
| SANOFI-AVENTIS U.S. LLC | $93.27 | 5 |
| Novo Nordisk Inc | $87.56 | 4 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $82.09 | 4 |
| Mannkind Corporation | $73.80 | 3 |
| Janssen Pharmaceuticals, Inc | $68.11 | 4 |
| Corcept Therapeutics | $58.02 | 3 |
| Radius Health, Inc. | $44.52 | 2 |
| Lilly USA, LLC | $38.38 | 3 |
| Alexion Pharmaceuticals, Inc. | $32.28 | 1 |
Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
EDUARDO DUSTY LUNA
NPI 1073959326 · CMS profile ID 650321
Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
EDINBURG, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1073959326?year=2019&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- EDUARDO DUSTY LUNA, NPI 1073959326, CMS profile ID 650321. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073959326?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). EDUARDO DUSTY LUNA, NPI 1073959326, CMS profile ID 650321. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073959326?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- EDUARDO DUSTY LUNA, NPI 1073959326, CMS profile ID 650321, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1073959326?year=2019&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
146 matching records · $24,743.20 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–146 of 146.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $107.55 | 04/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679361057 | CMS |
| Janssen Pharmaceuticals, Inc | $17.86 | 04/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658944257 | CMS |
| Amgen Inc. | $24.17 | 04/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662318371 | CMS |
| Merck Sharp & Dohme Corporation | $12.15 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695425591 | CMS |
| Abbott Laboratories | $11.67 | 04/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679361143 | CMS |
| Abbott Laboratories | $3.29 | 04/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679364143 | CMS |
| Abbott Laboratories | $5.87 | 04/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679364631 | CMS |
| Abbott Laboratories | $6.36 | 04/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679364799 | CMS |
| Abbott Laboratories | $1,250.00 | 04/09/2019 | Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679361477 | CMS |
| Abbott Laboratories | $135.25 | 04/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679361785 | CMS |
| Abbott Laboratories | $525.00 | 04/09/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679364675 | CMS |
| Merck Sharp & Dohme Corporation | $5.52 | 04/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695396471 | CMS |
| Alexion Pharmaceuticals, Inc. | $32.28 | 04/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695485039 | CMS |
| Merck Sharp & Dohme Corporation | $5.63 | 03/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695379467 | CMS |
| Radius Health, Inc. | $20.05 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 683950679 | CMS |
| Radius Health, Inc. | $24.47 | 03/26/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 683950685 | CMS |
| Abbott Laboratories | $218.75 | 03/25/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679363619 | CMS |
| Abbott Laboratories | $900.00 | 03/25/2019 | Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679365231 | CMS |
| Abbott Laboratories | $0.50 | 03/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679360923 | CMS |
| Abbott Laboratories | $5.65 | 03/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679364619 | CMS |
| Abbott Laboratories | $8.52 | 03/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679365067 | CMS |
| Abbott Laboratories | $86.76 | 03/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679365131 | CMS |
| Abbott Laboratories | $117.56 | 03/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679361241 | CMS |
| Lilly USA, LLC | $13.44 | 03/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657803509 | CMS |
| Abbott Laboratories | $5.19 | 03/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679364611 | CMS |
| Abbott Laboratories | $5.84 | 03/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679364629 | CMS |
| Merck Sharp & Dohme Corporation | $12.55 | 03/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695323713 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.74 | 02/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700080539 | CMS |
| Abbott Laboratories | $111.72 | 02/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679361195 | CMS |
| Abbott Laboratories | $111.72 | 02/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679361197 | CMS |
| Abbott Laboratories | $161.63 | 02/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679362763 | CMS |
| Abbott Laboratories | $161.63 | 02/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679362765 | CMS |
| Abbott Laboratories | $294.73 | 02/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679364131 | CMS |
| Abbott Laboratories | $690.64 | 02/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679364901 | CMS |
| Abbott Laboratories | $7.99 | 02/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 696944413 | CMS |
| Merck Sharp & Dohme Corporation | $6.81 | 02/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695263131 | CMS |
| SANOFI-AVENTIS U.S. LLC | $12.25 | 02/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694274269 | CMS |
| Abbott Laboratories | $90.99 | 02/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679365219 | CMS |
| Lilly USA, LLC | $13.46 | 02/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657792915 | CMS |
| SANOFI-AVENTIS U.S. LLC | $18.99 | 02/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693924097 | CMS |
| Merck Sharp & Dohme Corporation | $7.43 | 02/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695226469 | CMS |
| Abbott Laboratories | $9.38 | 01/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679365195 | CMS |
| SANOFI-AVENTIS U.S. LLC | $21.34 | 01/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693900001 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.59 | 01/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700040553 | CMS |
| Merck Sharp & Dohme Corporation | $16.14 | 01/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695218751 | CMS |
| Abbott Laboratories | $30.83 | 01/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679364173 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $3,123,757.93 | 45 |
| PY2024 | Recipient | $42,164.92 | 13 |
| PY2024 | Principal investigator | $2,429,401.71 | 40 |
| PY2023 | Recipient | $22,795.95 | 5 |
| PY2023 | Principal investigator | $781,915.42 | 13 |
| PY2022 | Recipient | $15,816.00 | 4 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
45 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $7,968.00 | 12/31/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism | No dispute reported | 06/30/2026 | 1202534293 |
| Principal investigator 1 | Eli Lilly and Company | $915.38 | 12/17/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES | No dispute reported | 06/30/2026 | 1187891202 |
| Principal investigator 1 | Eli Lilly and Company | $934.02 | 12/17/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES | No dispute reported | 06/30/2026 | 1187891764 |
| Principal investigator 1 | ABBVIE INC. | $4,820.64 | 12/05/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202529442 |
| Principal investigator 1 | Amgen Inc. | $306.08 | 11/10/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH | A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1246649363 |
| Principal investigator 1 | ABBVIE INC. | $24,228.60 | 11/05/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202521733 |
| Principal investigator 1 | ABBVIE INC. | $4,338.64 | 10/09/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202513909 |
| Principal investigator 1 | ABBVIE INC. | $8,672.00 | 10/09/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202513911 |
| Principal investigator 1 | ABBVIE INC. | $12,328.80 | 10/09/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202513913 |
| Principal investigator 1 | ABBVIE INC. | $21,984.60 | 09/04/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202508864 |
| Principal investigator 1 | ABBVIE INC. | $19,833.00 | 08/06/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202502270 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,823.00 | 07/28/2025 | Non-covered Recipient Entity COMPREHENSIVE CENTER | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190312719 |
| Principal investigator 1 | ABBVIE INC. | $9,698.04 | 07/02/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202494749 |
| Principal investigator 1 | ABBVIE INC. | $39,732.00 | 06/03/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202489725 |
| Principal investigator 1 | Eli Lilly and Company | $143,697.00 | 05/12/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND LONG-TERM SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-2) | No dispute reported | 06/30/2026 | 1187892142 |
| Principal investigator 1 | ABBVIE INC. | $13,713.48 | 05/07/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202483771 |
| Principal investigator 1 | Eli Lilly and Company | $155,888.00 | 05/06/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A PARALLEL-GROUP TREATMENT, PHASE 2, DOUBLE-BLIND STUDY OF ONCE-WEEKLY SUBCUTANEOUS LY3457263 COMPARED TO PLACEBO IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS ON A STABLE DOSE OF TIRZEPATIDE OR SEMAGLUTIDE WHO FAILED TO ACHIEVE HBA1C GOAL | No dispute reported | 06/30/2026 | 1187893342 |
| Principal investigator 1 | ABBVIE INC. | $4,308.48 | 04/03/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202471169 |
| Principal investigator 1 | ABBVIE INC. | $10,449.12 | 03/07/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202459620 |
| Principal investigator 1 | Eli Lilly and Company | $15,100.00 | 02/11/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187892138 |
| Principal investigator 1 | ABBVIE INC. | $28,311.36 | 02/06/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202449447 |
| Principal investigator 1 | Eli Lilly and Company | $81,790.00 | 02/03/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | No dispute reported | 06/30/2026 | 1187891194 |
| Principal investigator 1 | Eli Lilly and Company | $610,508.00 | 02/03/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) | No dispute reported | 06/30/2026 | 1187892124 |
| Principal investigator 1 | Eli Lilly and Company | $1,552.56 | 01/31/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR | No dispute reported | 06/30/2026 | 1187892140 |
| Principal investigator 1 | Eli Lilly and Company | $3,364.14 | 01/31/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1187893488 |
| Principal investigator 1 | Eli Lilly and Company | $3,812.36 | 01/31/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187893490 |
| Principal investigator 1 | Eli Lilly and Company | $10,300.59 | 01/31/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187893492 |
| Principal investigator 1 | Eli Lilly and Company | $364,700.00 | 01/28/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDITIES IN ADOLESCENTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED TRIAL (SURMOUNT-ADOLESCENTS-2) | No dispute reported | 06/30/2026 | 1187892808 |
| Principal investigator 1 | Eli Lilly and Company | $11,658.97 | 01/24/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDITIES IN ADOLESCENTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED TRIAL (SURMOUNT-ADOLESCENTS-2) | No dispute reported | 06/30/2026 | 1187890552 |
| Principal investigator 1 | Eli Lilly and Company | $3,235.35 | 01/24/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187893494 |
| Principal investigator 1 | Eli Lilly and Company | $102,825.00 | 01/21/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1187890554 |
| Principal investigator 1 | Eli Lilly and Company | $119,034.00 | 01/21/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR | No dispute reported | 06/30/2026 | 1187890556 |
| Principal investigator 1 | Eli Lilly and Company | $113,072.00 | 01/21/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187890786 |
| Principal investigator 1 | Eli Lilly and Company | $114,332.00 | 01/21/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187891196 |
| Principal investigator 1 | Eli Lilly and Company | $2,557.06 | 01/21/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187892122 |
| Principal investigator 1 | Eli Lilly and Company | $2,144.18 | 01/20/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187890558 |
| Principal investigator 1 | Eli Lilly and Company | $13,833.32 | 01/09/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187891762 |
| Principal investigator 1 | Eli Lilly and Company | $3,372.30 | 01/09/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187893486 |
| Principal investigator 1 | Eli Lilly and Company | $299,948.00 | 01/07/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187890788 |
| Principal investigator 1 | Eli Lilly and Company | $49,694.00 | 01/07/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187891198 |
| Principal investigator 1 | Eli Lilly and Company | $42,958.00 | 01/07/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A STUDY OF ORFORGLIPRON (LY3502970) IN PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH INSULIN GLARGINE, WITH OR WITHOUT METFORMIN AND/?OR SGLT-2 INHIBITOR (ACHIEVE-5) | No dispute reported | 06/30/2026 | 1187891200 |
| Principal investigator 1 | Eli Lilly and Company | $617,110.00 | 01/07/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187893344 |
| Principal investigator 1 | Eli Lilly Export S.A. Puerto Rico Branch | $3,530.19 | 01/03/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A STUDY OF ORFORGLIPRON (LY3502970) IN PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH INSULIN GLARGINE, WITH OR WITHOUT METFORMIN AND/?OR SGLT-2 INHIBITOR (ACHIEVE-5) | No dispute reported | 06/30/2026 | 1187891766 |
| Principal investigator 1 | Eli Lilly and Company | $4,523.20 | 01/02/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | No dispute reported | 06/30/2026 | 1187891760 |
| Principal investigator 1 | Eli Lilly and Company | $8,852.47 | 01/02/2025 | Non-covered Recipient Entity TEXAS VALLEY CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) | No dispute reported | 06/30/2026 | 1187892806 |